Gilead Sciences, Inc. vs Kimberly Clark Corp — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while Kimberly Clark Corp trades at $108.46 (market cap $36.11B). The key difference: Gilead Sciences, Inc. is far larger — about 4.7× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (4.72%). Which is the better fit depends on your goals.
| GILD | KMB | |
|---|---|---|
Market Cap | $168.35B | $36.11B |
Sector | Health | Consumer Staples |
52-Week High | $155.80 | $134.81 |
52-Week Low | $110.56 | $93.05 |
Enterprise Value | $191.42B | $41.67B |
Dividend Yield | 2.42% | 4.72% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Kimberly-Clark (KMB) trades at $108.95, up 0.86% on the day, with a neutral technical signal. The stock shows strong profitability with a net income margin of 11.79% and a high ROE of 129.43%, though revenue declined to $16.45B in 2025. Recent Q2 2026 earnings missed expectations, and the company cut its 2026 outlook due to challenges in China and softer consumer demand, as reported by Reuters on August 4, 2026.
The outlook is mixed; KMB offers a solid dividend yield and trades below the consensus price target of $113.20, but near-term headwinds from China and volatile shipments pose risks. Analyst sentiment is cautious with 61.29% hold ratings, reflecting balanced optimism for long-term value against short-term operational pressures.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →